Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

424 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase I study of S-1 with concurrent thoracic radiotherapy in elderly patients with localized advanced non-small cell lung cancer.
Takigawa N, Kiura K, Hotta K, Hosokawa S, Nogami N, Aoe K, Gemba K, Fujiwara K, Harita S, Takemoto M, Himei K, Shinkai T, Fujiwara Y, Takata S, Tabata M, Kanazawa S, Tanimoto M; Okayama Lung Cancer Study Group. Takigawa N, et al. Among authors: shinkai t. Lung Cancer. 2011 Jan;71(1):60-4. doi: 10.1016/j.lungcan.2010.04.012. Epub 2010 May 6. Lung Cancer. 2011. PMID: 20451285 Clinical Trial.
Clinical and pharmacokinetic study of docetaxel in elderly non-small-cell lung cancer patients.
Takigawa N, Segawa Y, Kishino D, Fujiwara K, Tokuda Y, Seki N, Shinkai T, Watanabe Y, Hiraki S, Kozuki T, Gemba K, Tabata M, Kiura K, Ueoka H, Tanimoto M. Takigawa N, et al. Among authors: shinkai t. Cancer Chemother Pharmacol. 2004 Sep;54(3):230-6. doi: 10.1007/s00280-004-0826-x. Epub 2004 May 4. Cancer Chemother Pharmacol. 2004. PMID: 15127232 Clinical Trial.
A phase I and pharmacological study of amrubicin and topotecan in patients of small-cell lung cancer with relapsed or extensive-disease small-cell lung cancer.
Shibayama T, Hotta K, Takigawa N, Tada A, Ueoka H, Harita S, Kiura K, Tabata M, Segawa Y, Nogami N, Kuyama S, Shinkai T, Tanimoto M. Shibayama T, et al. Among authors: shinkai t. Lung Cancer. 2006 Aug;53(2):189-95. doi: 10.1016/j.lungcan.2006.05.008. Epub 2006 Jun 27. Lung Cancer. 2006. PMID: 16806573 Clinical Trial.
A phase II trial of cisplatin and irinotecan alternating with doxorubicin, cyclophosphamide and etoposide in previously untreated patients with extensive-disease small-cell lung cancer.
Tabata M, Kiura K, Okimoto N, Segawa Y, Shinkai T, Yonei T, Kuyama S, Harita S, Hotta K, Ueoka H, Tanimoto M. Tabata M, et al. Among authors: shinkai t. Cancer Chemother Pharmacol. 2007 Jun;60(1):1-6. doi: 10.1007/s00280-006-0336-0. Epub 2007 Mar 29. Cancer Chemother Pharmacol. 2007. PMID: 17393168 Clinical Trial.
Triple combination chemotherapy with cisplatin, docetaxel, and irinotecan for advanced non-small cell lung cancer: a phase I/II trial.
Kiura K, Takigawa N, Segawa Y, Tabata M, Shibayama T, Gemba K, Bessho A, Fujimoto N, Takata I, Hotta K, Fujiwara K, Tokuda Y, Kuyama S, Shinkai T, Ueoka H, Tanimoto M; Okayama Lung Cancer Study Group. Kiura K, et al. Among authors: shinkai t. J Thorac Oncol. 2007 Jan;2(1):44-50. doi: 10.1097/JTO.0b013e31802bafe2. J Thorac Oncol. 2007. PMID: 17410009 Free article. Clinical Trial.
A phase II study of amrubicin and topotecan combination therapy in patients with relapsed or extensive-disease small-cell lung cancer: Okayama Lung Cancer Study Group Trial 0401.
Nogami N, Hotta K, Kuyama S, Kiura K, Takigawa N, Chikamori K, Shibayama T, Kishino D, Hosokawa S, Tamaoki A, Harita S, Tabata M, Ueoka H, Shinkai T, Tanimoto M. Nogami N, et al. Among authors: shinkai t. Lung Cancer. 2011 Oct;74(1):80-4. doi: 10.1016/j.lungcan.2011.01.018. Epub 2011 Feb 18. Lung Cancer. 2011. PMID: 21334093 Free article. Clinical Trial.
Benefits and adverse events among elderly patients receiving concurrent chemoradiotherapy for locally advanced non-small cell lung cancer: analysis of the Okayama Lung Cancer Study Group trial 0007.
Takigawa N, Kiura K, Segawa Y, Hotta K, Tamaoki A, Tokuda Y, Nagata T, Watanabe K, Gemba K, Moritaka T, Horita N, Takeda H, Okimoto N, Takemoto M, Matsuo K, Shinkai T, Tabata M, Ueoka H, Kanazawa S, Tanimoto M. Takigawa N, et al. Among authors: shinkai t. J Thorac Oncol. 2011 Jun;6(6):1087-91. doi: 10.1097/JTO.0b013e318213f86a. J Thorac Oncol. 2011. PMID: 21415777 Free article. Clinical Trial.
Factor associated with failure to administer subsequent treatment after progression in the first-line chemotherapy in EGFR-mutant non-small cell lung cancer: Okayama Lung Cancer Study Group experience.
Kato Y, Hotta K, Takigawa N, Nogami N, Kozuki T, Sato A, Ichihara E, Kudo K, Oze I, Tabata M, Shinkai T, Tanimoto M, Kiura K. Kato Y, et al. Among authors: shinkai t. Cancer Chemother Pharmacol. 2014 May;73(5):943-50. doi: 10.1007/s00280-014-2425-9. Epub 2014 Mar 16. Cancer Chemother Pharmacol. 2014. PMID: 24633759
424 results